Citation: | Liu Qixing, Li Yuehong. The latest progress on novel coronavirus vaccination in kidney transplant recipients[J]. ORGAN TRANSPLANTATION, 2023, 14(1): 135-141. doi: 10.3969/j.issn.1674-7445.2023.01.018 |
[1] |
CAILLARD S, ANGLICHEAU D, MATIGNON M, et al. An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants[J]. Kidney Int, 2020, 98(6): 1549-1558. DOI: 10.1016/j.kint.2020.08.005.
|
[2] |
CRAVEDI P, MOTHI SS, AZZI Y, et al. COVID-19 and kidney transplantation: results from the TANGO International Transplant Consortium[J]. Am J Transplant, 2020, 20(11): 3140-3148. DOI: 10.1111/ajt.16185.
|
[3] |
GANDOLFINI I, CRESPO M, HELLEMANS R, et al. Issues regarding COVID-19 in kidney transplantation in the ERA of the Omicron variant: a commentary by the ERA Descartes Working Group[J]. Nephrol Dial Transplant, 2022, 37(10): 1824-1829. DOI: 10.1093/ndt/gfac203.
|
[4] |
COCHRAN W, SHAH P, BARKER L, et al. COVID-19 clinical outcomes in solid organ transplant recipients during the Omicron surge[J]. Transplantation, 2022, 106(7): e346-e347. DOI: 10.1097/TP.0000000000004162.
|
[5] |
BERTRAND D, LAURENT C, LEMÉE V, et al. Efficacy of anti-SARS-CoV-2 monoclonal antibody prophylaxis and vaccination on the Omicron variant of COVID-19 in kidney transplant recipients[J]. Kidney Int, 2022, 102(2): 440-442. DOI: 10.1016/j.kint.2022.05.007.
|
[6] |
SAHIN U, MUIK A, VOGLER I, et al. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans[J]. Nature, 2021, 595(7868): 572-577. DOI: 10.1038/s41586-021-03653-6.
|
[7] |
KHOURY DS, CROMER D, REYNALDI A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection[J]. Nat Med, 2021, 27(7): 1205-1211. DOI: 10.1038/s41591-021-01377-8.
|
[8] |
FIOLET T, KHERABI Y, MACDONALD CJ, et al. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review[J]. Clin Microbiol Infect, 2022, 28(2): 202-221. DOI: 10.1016/j.cmi.2021.10.005.
|
[9] |
CAILLARD S, THAUNAT O. COVID-19 vaccination in kidney transplant recipients[J]. Nat Rev Nephrol, 2021, 17(12): 785-787. DOI: 10.1038/s41581-021-00491-7.
|
[10] |
SATTLER A, SCHREZENMEIER E, WEBER UA, et al. Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (Tozinameran) prime-boost vaccination in kidney transplant recipients[J]. J Clin Invest, 2021, 131(14): e150175. DOI: 10.1172/JCI150175.
|
[11] |
CAILLARD S, CHAVAROT N, BERTRAND D, et al. Occurrence of severe COVID-19 in vaccinated transplant patients[J]. Kidney Int, 2021, 100(2): 477-479. DOI: 10.1016/j.kint.2021.05.011.
|
[12] |
BENNING L, MORATH C, BARTENSCHLAGER M, et al. Neutralization of SARS-CoV-2 variants of concern in kidney transplant recipients after standard COVID-19 vaccination[J]. Clin J Am Soc Nephrol, 2022, 17(1): 98-106. DOI: 10.2215/CJN.11820921.
|
[13] |
AL JURDI A, GASSEN RB, BORGES TJ, et al. Suboptimal antibody response against SARS-CoV-2 Omicron variant after third dose of mRNA vaccine in kidney transplant recipients[J]. Kidney Int, 2022, 101(6): 1282-1286. DOI: 10.1016/j.kint.2022.04.009.
|
[14] |
KAMAR N, ABRAVANEL F, MARION O, et al. Three doses of an mRNA COVID-19 vaccine in solid-organ transplant recipients[J]. N Engl J Med, 2021, 385(7): 661-662. DOI: 10.1056/NEJMc2108861.
|
[15] |
BENOTMANE I, GAUTIER G, PERRIN P, et al. Antibody response after a third dose of the mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients with minimal serologic response to 2 doses[J]. JAMA, 2021, 326(11): 1063-1065. DOI: 10.1001/jama.2021.12339.
|
[16] |
HALL VG, FERREIRA VH, KU T, et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients[J]. N Engl J Med, 2021, 385(13): 1244-1246. DOI: 10.1056/NEJMc2111462.
|
[17] |
MASSET C, KERLEAU C, GARANDEAU C, et al. A third injection of the BNT162b2 mRNA COVID-19 vaccine in kidney transplant recipients improves the humoral immune response[J]. Kidney Int, 2021, 100(5): 1132-1135. DOI: 10.1016/j.kint.2021.08.017.
|
[18] |
MASSA F, CREMONI M, GÉRARD A, et al Safety and cross-variant immunogenicity of a three-dose COVID-19 mRNA vaccine regimen in kidney transplant recipients[J]. EBioMedicine, 2021, 73: 103679. DOI: 10.1016/j.ebiom.2021.103679.
|
[19] |
KUMAR D, HU Q, SAMSON R, et al. Neutralization against Omicron variant in transplant recipients after three doses of mRNA vaccine[J]. Am J Transplant, 2022, 22(8): 2089-2093. DOI: 10.1111/ajt.17020.
|
[20] |
CAILLARD S, THAUNAT O, BENOTMANE I, et al. Antibody response to a fourth messenger RNA COVID-19 vaccine dose in kidney transplant recipients: a case series[J]. Ann Intern Med, 2022, 175(3): 455-456. DOI: 10.7326/L21-0598.
|
[21] |
OSMANODJA B, RONICKE S, BUDDE K, et al. Serological response to three, four and five doses of SARS-CoV-2 vaccine in kidney transplant recipients[J]. J Clin Med, 2022, 11(9): 2565. DOI: 10.3390/jcm11092565.
|
[22] |
BENOTMANE I, BRUEL T, PLANAS D, et al. A fourth dose of the mRNA-1273 SARS-CoV-2 vaccine improves serum neutralization against the Delta variant in kidney transplant recipients[J]. Kidney Int, 2022, 101(5): 1073-1076. DOI: 10.1016/j.kint.2022.02.011.
|
[23] |
CHARMETANT X, ESPI M, BENOTMANE I, et al. Infection or a third dose of mRNA vaccine elicits neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients[J]. Sci Transl Med, 2022, 14(636): eabl6141. DOI: 10.1126/scitranslmed.abl6141.
|
[24] |
BENOTMANE I, GAUTIER-VARGAS G, GALLAIS F, et al. Strong antibody response after a first dose of a SARS-CoV-2 mRNA-based vaccine in kidney transplant recipients with a previous history of COVID-19[J]. Am J Transplant, 2021, 21(11): 3808-3810. DOI: 10.1111/ajt.16764.
|
[25] |
BENNING L, MORATH C, BARTENSCHLAGER M, et al. Natural SARS-CoV-2 infection results in higher neutralization response against variants of concern compared with 2-dose BNT162b2 vaccination in kidney transplant recipients[J]. Kidney Int, 2022, 101(3): 639-642. DOI: 10.1016/j.kint.2021.12.009.
|
[26] |
ZONG K, PENG D, YANG H, et al. Risk factors for weak antibody response of SARS-CoV-2 Vaccine in adult solid organ transplant recipients: a systemic review and meta-analysis[J]. Front Immunol, 2022, 13: 888385. DOI: 10.3389/fimmu.2022.888385.
|
[27] |
ROZEN-ZVI B, YAHAV D, AGUR T, et al. Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study[J]. Clin Microbiol Infect, 2021, 27(8): 1173. e1-1173. e4. DOI: 10.1016/j.cmi.2021.04.028.
|
[28] |
KANTAUSKAITE M, MÜLLER L, KOLB T, et al. Intensity of mycophenolate mofetil treatment is associated with an impaired immune response to SARS-CoV-2 vaccination in kidney transplant recipients[J]. Am J Transplant, 2022, 22(2): 634-639. DOI: 10.1111/ajt.16851.
|
[29] |
NETTI GS, INFANTE B, TROISE D, et al. mTOR inhibitors improve both humoral and cellular response to SARS-CoV-2 messenger RNA BNT16b2 vaccine in kidney transplant recipients[J]. Am J Transplant, 2022, 22(5): 1475-1482. DOI: 10.1111/ajt.16958.
|
[30] |
CHAVAROT N, OUEDRANI A, MARION O, et al. Poor anti-SARS-CoV-2 humoral and T-cell responses after 2 injections of mRNA vaccine in kidney transplant recipients treated with belatacept[J]. Transplantation, 2021, 105(9): e94-e95. DOI: 10.1097/TP.0000000000003784.
|
[31] |
REGELE F, HEINZEL A, HU K, et al. Stopping of mycophenolic acid in kidney transplant recipients for 2 weeks peri-vaccination does not increase response to SARS-CoV-2 vaccination-a non-randomized, controlled pilot study[J]. Front Med (Lausanne), 2022, 9: 914424. DOI: 10.3389/fmed.2022.914424.
|
[32] |
BENOTMANE I, GAUTIER-VARGAS G, COGNARD N, et al. Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine[J]. Kidney Int, 2021, 99(6): 1498-1500. DOI: 10.1016/j.kint.2021.04.005.
|
[33] |
GRUPPER A, RABINOWICH L, SCHWARTZ D, et al. Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus[J]. Am J Transplant, 2021, 21(8): 2719-2726. DOI: 10.1111/ajt.16615.
|
[34] |
MARION O, DEL BELLO A, ABRAVANEL F, et al. Safety and immunogenicity of anti-SARS-CoV-2 messenger RNA vaccines in recipients of solid organ transplants[J]. Ann Intern Med, 2021, 174(9): 1336-1338. DOI: 10.7326/M21-1341.
|
[35] |
CUCCHIARI D, EGRI N, BODRO M, et al. Cellular and humoral response after mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients[J]. Am J Transplant, 2021, 21(8): 2727-2739. DOI: 10.1111/ajt.16701.
|
[36] |
MIDTVEDT K, TRAN T, PARKER K, et al. Low immunization rate in kidney transplant recipients also after dose 2 of the BNT162b2 vaccine: continue to keep your guard up![J]. Transplantation, 2021, 105(8): e80-e81. DOI: 10.1097/TP.0000000000003856.
|
[37] |
WERBEL WA, BOYARSKY BJ, OU MT, et al. Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients: a case series[J]. Ann Intern Med, 2021, 174(9): 1330-1332. DOI: 10.7326/L21-0282.
|
[38] |
STUMPF J, TONNUS W, PALIEGE A, et al. Cellular and humoral immune responses after 3 doses of BNT162b2 mRNA SARS-CoV-2 vaccine in kidney transplant[J]. Transplantation, 2021, 105(11): e267-e269. DOI: 10.1097/TP.0000000000003903.
|